Clover Health Investments, Corp (CLOV) Stock Price & How to Invest

Clover Health Investments, Corp. is a US healthcare-technology company that offers Medicare Advantage plans, the private alternative to traditional Medicare, primarily to seniors. Unlike many rivals that lean on narrow-network HMO plans, Clover concentrates on wide-network PPO plans that let members see a broad range of doctors, which the company argues is a differentiator for seniors who value choice. At the heart of the business is Clover Assistant, a proprietary software platform that pulls together patient data and surfaces insights to physicians at the point of care, aiming to catch chronic conditions earlier and manage costs more effectively than a traditional insurer.

After years of losses common to fast-growing insurtechs, Clover's recent narrative is a turn toward profitability. The company reported strong Medicare Advantage membership growth into the 2026 plan year, with membership up roughly 50% year over year to around 150,000-plus members, and it guided to full-year 2026 revenues in the multi-billion-dollar range with positive adjusted EBITDA and its first year of GAAP net income profitability. A favorable revision of its 2026 CMS Star Rating for its main PPO contract (raised to 4.5 stars after a court order, covering the large majority of members) is a meaningful tailwind because higher Star Ratings drive bonus payments and rebates. The investment picture combines rapid membership growth and improving economics against the backdrop of a heavily regulated, competitive market dominated by much larger insurers.

The dominant risk is that Clover is a small insurer competing against giants like UnitedHealth, Humana, CVS/Aetna, and Centene, which have far greater scale, capital, and provider leverage. Medicare Advantage economics are highly sensitive to the medical-cost ratio: if members use more care than priced, a fast-growing book can swing back to losses quickly. The business is heavily dependent on CMS policy, reimbursement rates, risk-adjustment rules, and Star Ratings, all of which are outside the company's control and can change materially between plan years. Profitability is recent and not yet long-proven, so the turn could reverse if growth outpaces cost discipline. Insurtech peers such as Alignment Healthcare, Oscar Health, and Devoted Health add competitive pressure, and the stock has historically been volatile with elevated retail and short-interest attention.

3 analysts publish price targets on CLOV, averaging $4.58 against a $4.17 price as of August 2026, or +9.8%. The published targets run from $3.50 to $5.50, a moderate spread, and the ratings split 1 buy, 2 hold, 0 sell. Over the last six months there have been 3 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CLOV forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Clover Health Investments, Corp. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Medicare Advantage membership growth. Clover has been growing membership far faster than the broader Medicare Advantage market, with roughly 50% year-over-year growth into the 2026 plan year and guidance for continued expansion. The most optimistic published target, $5.50, assumes this works close to its best case.

The case against. The dominant risk is that Clover is a small insurer competing against giants like UnitedHealth, Humana, CVS/Aetna, and Centene, which have far greater scale, capital, and provider leverage. The most pessimistic target, $3.50, is roughly what CLOV is worth if this bites instead.

Read the full bull and bear case on CLOV, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Clover Health Investments, Corp's investor relations page or your broker.

• Medicare Advantage membership: ~150,000-plus members, up roughly 50% year over year into the 2026 plan year (approximate; verify live)
• 2026 revenue guidance: Guided to the multi-billion-dollar range (roughly $2.8B to $2.9B midpoint framing; approximate)
• Profitability: Guided to positive adjusted EBITDA and first full-year GAAP net income profitability in 2026
• 2026 CMS Star Rating: Main PPO contract raised to 4.5 stars (after a court order), covering the large majority of members
• Business model: Wide-network PPO Medicare Advantage plans plus the Clover Assistant software platform
• Valuation framing: Small-cap insurer; check current price, market cap, and how the market prices its growth-versus-profit turn on a live source

All figures here are approximate and tied to the asOf date; verify live numbers before acting. For a fast-growing insurer, the medical-cost ratio (medical claims as a share of premiums), membership growth, and Star Ratings matter more than any single headline number, because small changes in medical costs can swing profitability sharply. Guidance and Star Ratings can be revised, so confirm the latest quarter and CMS status directly rather than relying on these approximations.

Other names that sit close to CLOV: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CLOV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CLOV sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CLOV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Clover Health is a bet on a small, technology-driven Medicare Advantage insurer scaling its PPO membership and Clover Assistant platform toward durable profitability. It rewards continued fast growth and controlled medical costs, and it is exposed to CMS policy, Star Ratings, medical-cost inflation, and competition from far larger insurers.

Whether CLOV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CLOV a buy or a sell?, and where the stock could go from here in the CLOV stock forecast.

For income investors, whether CLOV pays a dividend and how the payout looks is covered in does CLOV pay a dividend? And to weigh CLOV against a peer, read the full side-by-side comparisons: CLOV vs UNH and CLOV vs HUM.